We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

By LabMedica International staff writers
Posted on 31 Jan 2025
Print article
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised individuals. One of the major challenges in diagnosing pneumonia is the difficulty in obtaining an appropriate sample, and frequently, no pathogen is identified. Without a clear microbiological diagnosis, broad-spectrum antibiotics are typically administered, which increases the risk of antibiotic resistance and poor patient outcomes if the wrong antibiotics are chosen. The absence of rapid and accurate diagnostic tools only worsens this situation, hindering the ability to provide tailored treatments and leading to the overuse of antibiotics. Researchers are now exploring the possibility of detecting bacterial pneumonia directly from blood samples to improve access to LRTI testing.

Rhode Island Hospital (Providence, RI, USA) has been awarded USD 1 million by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, CARB-X, Boston, MA, USA) to develop a polymerase chain reaction (PCR) method informed by RNA sequencing to detect bacterial pneumonia directly from whole blood. CARB-X is a global non-profit collaboration focused on supporting early-stage research and development of antibacterial therapies to combat the growing problem of antibiotic resistance. The aim is to detect pneumonias caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae, using whole blood samples, making it less invasive compared to traditional methods that require samples from the airways, such as bronchoscopy or deep suctioning.

This simplified approach, involving a needle-stick blood collection from the arm, has the potential to expand access to testing and streamline current LRTI testing methods, enabling testing at primary care centers around the world instead of just tertiary care settings. Unlike traditional microbiological tests, this method will not require specimen culturing, providing results in just four hours. Targeting RNA ensures that the infection is active, as RNA degrades much faster than DNA, lasting only minutes to hours when sourced from bacteria. This technique immediately stabilizes the RNA for testing, and because it targets RNA, it identifies bacteria actively producing resistance proteins, rather than simply detecting bacteria that may carry genes for resistance.

“The support from CARB-X to focus on developing a direct from blood diagnostic for lower-respiratory-tract infections expands our current NIH supported work creating a direct from blood, culture independent, diagnostic for pathogens causing sepsis targeting RNA from the bacteria using RNA sequencing data form patients,” said Sean Monaghan, MD, surgeon at Rhode Island Hospital.

“This innovative diagnostic approach holds the potential to improve access to testing for lower-respiratory-tract infections, including pneumonia, enabling clinicians to make faster, more informed decisions and reduce the use of broad-spectrum antibiotics,” added Erin Duffy, PhD, Chief of R&D and CARB-X. “By supporting Rhode Island Hospital’s work, CARB-X is learning whether alternative sample types in detecting LRTIs is promising for future product development.”

Related Links:
Rhode Island Hospital
CARB-X

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.